Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Gallium Ga 68 N188 is a radiopharmaceutical composed of a nectin-4-targeting bicyclic peptide (N188) labeled with the positron-emitting radioisotope gallium-68. It is designed for use in PET/CT imaging to noninvasively quantify membranous nectin-4 expression in tumors. The agent binds specifically to nectin-4 (poliovirus receptor-like protein 4; PVRL4), an emerging biomarker overexpressed in several cancers including urothelial carcinoma, pancreatic cancer, intrahepatic cholangiocarcinoma, cervical cancer, and hepatocellular carcinoma. By visualizing and quantifying nectin-4 expression levels in vivo, [68Ga]N188 can help stratify patients for therapies targeting nectin-4 (such as enfortumab vedotin) and may assist with staging or restaging disease. Preclinical and clinical studies have demonstrated high affinity for nectin-4 and favorable pharmacokinetics and safety profiles[1][2][5][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on gallium Ga 68 N188.